Navigating Treatment Sequencing After Frontline Treatment Failure in CLL 30.01.2026 12:15

Faculty: Jennifer R. Brown, MD, PhD Faculty: William Mencia, MD, FACEHP This activity explores treatment sequencing strategies for chronic lymphocytic leukemia (CLL) following frontline therapy failure based on prior therapies, mechanisms of resistance, and minimal residual disease status. Dr. Jennifer Brown discusses how distinguishing between resistance and intolerance to BTK and BCL2 inhibitors...

It Takes a Village, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease 30.01.2026 10:00

Faculty: David Eichenbaum, MD In this didactic case presentation, Dr. David Eichenbaum discusses an 88-year-old patient with non-central geographic atrophy who received inappropriate bevacizumab treatment due to uncoordinated care after relocating seasonally. The case illustrates challenges that can arise in managing retinal disease across geographically distant sites. Dr. Eichenbaum emphasizes op...

A Case of Missed Diagnosis, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease 30.01.2026 16:00

Faculty: Esther Lee Kim, MD In this case-based presentation, Dr. Esther Lee Kim reviews a young patient with long-standing type 2 diabetes who presented with bilateral vision loss and was initially referred for possible retinal vein occlusion. The case underscores how demographic factors can inform the risk of rapid disease progression, even in the setting of a relatively controlled HbA1c. Dr. Kim...

Patient at High Risk of Loss to Follow-Up, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease 30.01.2026 15:30

Faculty: Deepak Sambhara, MD In this clinical discussion, Dr. Deepak Sambhara presents a case of a working-age man with severe non-proliferative diabetic retinopathy and diabetic macular edema. He details the diagnostic process using OCT and NIR imaging and explains how he engaged the patient in his treatment journey. Patient communication strategies are emphasized, as is a collaborative approach...

Overcoming Cultural and Communication Disconnects, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease 30.01.2026 14:30

Faculty: David Chin Yee, MD, FASRS In this case-based discussion, Dr. David Chin Yee presents his challenges and outcomes when managing a patient with diabetic macular edema who initially declined treatment due to language limitations, cultural beliefs, and mistrust of medical interventions. The case highlights the implementation of culturally sensitive strategies and underscores the value of cult...

RAS(ON) and Beyond: Clinical Integration and Strategic Sequencing 29.01.2026 5:45

Faculty: Kathryn Arbour Faculty: Eileen M. O'Reilly, MD This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, review early efficacy and safety data from agents such as daraxonrasib, elironrasib, and zoldonrasib, and highlight ongoing cl...

Novel RAS-Targeted Therapy: Prevention, Monitoring, and Mitigation of Adverse Events 29.01.2026 6:15

Faculty: Eileen M. O'Reilly, MD Faculty: Kathryn Arbour This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, review early efficacy and safety data from agents such as daraxonrasib, elironrasib, and zoldonrasib, and highlight ongoing cl...

Evaluating Use in Pancreatic Cancer: Efficacy and Safety Data for ON-State RAS Inhibitors 29.01.2026 5:45

Faculty: Eileen M. O'Reilly, MD This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, review early efficacy and safety data from agents such as daraxonrasib, elironrasib, and zoldonrasib, and highlight ongoing clinical trials. The activ...

NSCLC Data Review: Efficacy and Safety Data for ON-State RAS Inhibitors 29.01.2026 6:15

Faculty: Kathryn Arbour This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, review early efficacy and safety data from agents such as daraxonrasib, elironrasib, and zoldonrasib, and highlight ongoing clinical trials. The activity also addr...

Mechanistic Evolution in RAS Therapy: ON-State and Multi-Selective Targeting 29.01.2026 5:45

Faculty: Kathryn Arbour Faculty: Eileen M. O'Reilly, MD This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, review early efficacy and safety data from agents such as daraxonrasib, elironrasib, and zoldonrasib, and highlight ongoing cl...

Early Approaches to RAS Targeting: Efficacy Signals and Known Limitations 29.01.2026 6:15

Faculty: Kathryn Arbour Faculty: Eileen M. O'Reilly, MD This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, review early efficacy and safety data from agents such as daraxonrasib, elironrasib, and zoldonrasib, and highlight ongoing cl...

Unmet Need: Second-Line Outcomes Remain Poor for NSCLC and Pancreatic Cancer 29.01.2026 5:45

Faculty: Kathryn Arbour Faculty: Eileen M. O'Reilly, MD This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, review early efficacy and safety data from agents such as daraxonrasib, elironrasib, and zoldonrasib, and highlight ongoing cl...

RAS Across Tumors: Who to Test When 29.01.2026 6:00